Results 101 to 110 of about 1,481 (180)

Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials

Neuropsychiatric Disease and Treatment, 2021
Stephane Borentain,1 David Williamson,2,3 Ibrahim Turkoz,4 Vanina Popova,5 William V McCall,3 Maju Mathews,1 Frank Wiegand1 1Department of Global Medical Affairs, Janssen Research & Development, LLC, Titusville, NJ, USA; 2CNS Scientific Affairs Liaisons,
Borentain S, Williamson D, Turkoz I, Popova V, McCall WV, Mathews M, Wiegand F   +6 more
doaj  

Urological symptoms following ketamine treatment for psychiatric disorders:A systematic review [PDF]

Ketamine has emerged as a putative rapid-acting treatment option for psychiatric disorders, particularly treatment-resistant depression. Chronic recreational ketamine use is associated with ketamine-induced urological toxicity, raising concerns over the ...
Caulfield, Alice, Kerr Gaffney, Jess, Ritter, Phillip, Rucker, James, Tröger, Anna, Young, Allan   +5 more
core   +1 more source

Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression:Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study [PDF]

Patients with treatment resistant depression (TRD) experience a greater negative impact on their functioning and productivity at home and in the workplace versus treatment-responsive patients.
Cleare, Anthony
core   +2 more sources

Utilizing Esketamine Short-Term with New Oral Antidepressants in Patients with Treatment Resistant Depression and Suicidal Ideation to Minimize Post-Discharge Suicide Attempts: A Systematic Review [PDF]

, 2023
Purpose: To assess whether esketamine can be utilized short-term while waiting for a new oral antidepressant to reach therapeutic level in patients admitted for treatment resistant depression and suicidal ideation.
Montgomery, Ebony SY
core   +1 more source

Real-world evaluation of change in depressive symptoms among patients with treatment-resistant depression treated with esketamine

BMC Psychiatry
Background Treatment-resistant depression (TRD) is often characterized by inadequate response to ≥ 2 oral antidepressant treatments of adequate dose and duration during a major depressive episode (MDE). Esketamine nasal spray (ESK) was approved by the US
Carl D. Marci, Kruti Joshi, Stevan Geoffrey Severtson, Janis L. Breeze, Manish K. Jha   +4 more
doaj   +1 more source

Esketamine Nasal Spray

Pondicherry Journal of Nursing, 2020
Mohamed SJ Farhana, Subbarayan Dhivagar, Subramaniyan Prabavathy   +2 more
openaire   +1 more source

Clinical benefits and considerations of dextromethorphan and bupropion administered separately for managing depression: A case report [PDF]

Mental Health Clinician
MDD can affect anyone regardless of age, and it often starts during late teens or early adulthood. Although some patients with MDD have an adequate response to medications, only approximately 50% respond to the first treatment, and approximately 30% do ...
Parna Haghparast, PharmD, BCPS, Busuyi Olotu, BPharm, MSPharm, PhD, Carol Yuan, PharmD, BCPP   +2 more
doaj   +1 more source

Patient Experience with Intranasal Esketamine in Treatment-Resistant Depression: Insights from a Multicentric Italian Study (REAL-ESKperience) [PDF]

Background. Treatment-resistant depression (TRD) is a prevalent, high-burden disorder. Esketamine nasal spray (ESK-NS) has been approved for, T.R.D.; and efficacy has been observed in both clinical trials and real-world studies.
Andriola I., Barlati S., Carminati M., Cattaneo C. I., Clerici M., d'Andrea G., De Berardis D., De Filippis S., Dell'Osso B., Di Lorenzo G., Di Nicola M., Maina G., Manchia M., Marcatili M., Marcelli I., Martiadis V., Martinotti G., Niolu C., Pepe M., Petralia A., Pettorruso M., Rosso G., Sani G., Serafini G., Signorelli M. S., Vannucchi T., Vismara M., Vita A., Zanardi R.   +28 more
core   +1 more source

Auto-Induction in Oral Esketamine Treatment for Treatment-Resistant Depression:An Exploratory Study [PDF]

Background: Esketamine is a rapidly acting antidepressant with robust efficacy in treatment-resistant depression (TRD). Diminishing therapeutic effects and attenuated side effects have been reported after long-term use.
Kamphuis, Jeanine, Punt, Nieko C, Schoevers, Robert A, Smith-Apeldoorn, Sanne Y, Touw, Daan J, Veraart, Jolien K E, Visser, Dylan, Vos, Cornelis F, Wessels, Mireille A   +8 more
core   +1 more source

Comparative safety of prescribed Esketamine and ketamine in relation to renal and urinary disorders : A pharmacovigilance perspective [PDF]

© 2024 The Author(s). Published by Elsevier Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial 4.0 International License (CC BY-NC), https://creativecommons.org/licenses/by-nc/4.0/Intranasal
Arillotta, D, Chiappini, S, Corkery, J, D'Andrea, G, Floresta, G, Guirguis, A, Martinotti, G, Mosca, A, Papanti, G D, Schifano, F, Schifano, N, Semeraro, F   +11 more
core   +2 more sources